Based on the Immuneering Corp stock forecast from 3 analysts, the average analyst target price for Immuneering Corp is USD 12.20 over the next 12 months. Immuneering Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Immuneering Corp is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Immuneering Corp’s stock price was USD 1.99. Immuneering Corp’s stock price has changed by +2.58% over the past week, -15.68% over the past month and -65.09% over the last year.
No recent analyst target price found for Immuneering Corp
No recent average analyst rating found for Immuneering Corp
Company Overview Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Read Less
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cance...Read More
Frequently Asked Questions About Immuneering Corp (IMRX) Stock
Based on ratings from 3 analysts Immuneering Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on IMRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for IMRX is USD 12.20 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on IMRX's stock to indicate if its overvalued.
The last closing price of IMRX's stock was USD 1.99.
The most recent market capitalization for IMRX is USD 0.06B.
Based on targets from 3 analysts, the average taret price for IMRX is projected at USD 12.20 over the next 12 months.
This means that IMRX's stock price may go up by +513.07% over the next 12 months.
We can't find any ETFs which contains Immuneering Corp's stock.
As per our most recent records Immuneering Corp has 66 Employees.
Immuneering Corp's registered address is 245 Main Street, Cambridge, MA, United States, 02142.
You can get more information about it from Immuneering Corp's website at https://immuneering.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Immuneering Corp (IMRX) Stock
Based on ratings from 3 analysts Immuneering Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on IMRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for IMRX is USD 12.20 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on IMRX's stock to indicate if its overvalued.
The last closing price of IMRX's stock was USD 1.99.
The most recent market capitalization for IMRX is USD 0.06B.
Based on targets from 3 analysts, the average taret price for IMRX is projected at USD 12.20 over the next 12 months.
This means that IMRX's stock price may go up by +513.07% over the next 12 months.
We can't find any ETFs which contains Immuneering Corp's stock.
As per our most recent records Immuneering Corp has 66 Employees.
Immuneering Corp's registered address is 245 Main Street, Cambridge, MA, United States, 02142.
You can get more information about it from Immuneering Corp's website at https://immuneering.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IMRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
